DDMAC social media guidelines include "dislike" button for bad ads

Share this article:
Abrams: seeing how complex the issues are
Abrams: seeing how complex the issues are

Editor's note: April Fools!

The FDA surprised the industry by rolling out detailed social media marketing guidance and a beefed up “Bad Ad” program that will use crowdsourcing to inform federal formulary access decisions.

 
Just days after announcing it would miss a second deadline for the hotly anticipated draft guidance, the agency reversed course. At a hastily assembled press conference Friday morning, Division of Drug Marketing, Advertising and Communications director Tom Abrams outlined the new policy.
 
The theme of DDMAC's Good Guidance Practices, said Abrams, is "Back to the future."
 
"We believe that companies can best offer truthful, non-misleading and balanced information on regulated products through proven technology until those products are themselves proven," said DDMAC's Jean-Ah Kang. "Meaning that they've been on the market for, say, 13 years or so."
 
Accordingly, DDMAC will now require that all web pages for branded prescription pharmaceutical products be optimized for the Netscape Navigator browser. Pharmas, the agency said, may provide information about their products on Friendster, though not on Facebook, Twitter, YouTube, Orkut or even MySpace.
 
A "dislike" button, inspired by the agency's "Bad Ad" program, will be required for all content deemed promotional, and the data generated will inform the Independent Payment Advisory Board's recommendations for Medicare coverage. Search ads for regulated products will be required to carry a tag in flashing red script reading "WARNING! This site may harm your computer!"

In keeping with that guidance, the agency unveiled a revamped website with what Abrams hailed as a "cool retro-'90s look." A polka band played a cover of Nirvana's "Smells Like Teen Spirit" as Abrams fiddled with Powerpoint slides of the site.

Abrams fired a warning shot to marketers looking to imitate the behavior of “today's youth” in their digital communications. “Regulated industries should refrain from ‘sexting,' whatever that is,” he declared. “It just sounds nasty. Don't do it."
 
As predicted by MM&M back in February, Abrams named former Propecia marketer and viral videotrepreneur Kevin Nalty to lead a new division dedicated to policing online marketing.
 
"The Internet is great for porn, toilet humor and cute pictures of small, furry animals," said Nalty, "but disseminating information about prescription drugs? People, trust me -- stick to fart jokes and we'll all get along just fine."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...